Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (CLL)
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (CLL)
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.
Inclusion Criteria:
In- and outpatients suffering from CLL, who are treated with Mab Campath, and are routinely monitored with PCR (Polymerase Chain Reaction) for CMV infection during MabCampath treatment and for at least 2 months following completion of treatment.
Exclusion Criteria:
In accordance with Summaries of Product Characteristics (SPC).
Many Locations, Bosnia and Herzegovina
Many Locations, Israel
Many Locations, North Macedonia